Furthermore, Yang and colleagues proposed PAD4-related signatures as predictors of autoimmune disease activity, adding weight to the idea that PAD4 inhibitors, like Cl-amidine, could offer benefit beyond animal models [7]. This evidence concerns the gene PADI4 and autoimmune disease.